Could wet AMD patients get fewer eye shots? new study tests early treatment breaks
NCT ID NCT04932980
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two drugs, aflibercept and brolucizumab, for wet age-related macular degeneration (AMD). Instead of the usual three monthly loading doses, it tests starting with longer intervals between injections right away. The goal is to see if this approach works just as well while reducing the number of injections needed over a year. 80 patients aged 50 and older with active wet AMD are taking part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Aflibercept (Eylea) and Brolucizumab (Beovu) injections
- What this could lead to
- If successful, this could mean fewer eye injections for wet AMD patients without losing vision, making treatment less burdensome.
- What could go wrong
- This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The longer intervals might not control the disease as well as the standard approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Active MNV secondary to nAMD, going along with clinically significant vision loss * Patients aged 50 years or older of all sexes * Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the central subfield of the study eye on OCT * signed informed consent for this study prior to the screening visit * If possible: availability of a smartphone and willingness to perform self-testing with the Alleye app (soft criteria) Exclusion Criteria: * Any other cause of macular oedema * Structural damage to the macula precluding a visual potential * Optical media opacities not allowing an accurate performance of the protocol examinations * Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery * Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage * Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea * History of IVT with anti-VEGF or corticosteroids at any time in the study eye * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. * Significantly worse functional prognosis in the other eye or only eye * Women of childbearing potential not willing to use an effective method of contraception during treatment and until at least 3 months after the last treatment * Pregnant or lactating women * Any systemic auto-inflammatory and auto-immune disease requiring treatment * Treatment with high-dose corticosteroids (Prednisone equivalent \>5mg/day), immunosuppressive or immunomodulatory or anti-proliferative agents for any reason * Inability or contraindications to undergo the investigated intervention
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Wet age related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Berner Augenklinik
Bern, 3007, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drug goes Head-to-Head with standard treatment for wet AMD
- New eye drug goes Head-to-Head with standard care for wet AMD
- Eye drops could replace injections for wet AMD
- Could eye drops replace injections for a leading cause of blindness?
- Eye injection burden varies by disease, study finds
- New hope for wet AMD patients: a simple pill may drain stubborn eye fluid